Skip to Content

Zilretta Approval Status

  • FDA approved: No
  • Brand name: Zilretta
  • Generic name: triamcinolone acetonide
  • Dosage form: Sustained-Release Intra-Articular Injection
  • Company: Flexion Therapeutics, Inc.
  • Treatment for: Osteoarthritis

Zilretta (triamcinolone acetonide) is a sustained-release corticosteroid polymer (PLGA) formulation intended to provide persistent concentrations of drug locally to amplify the magnitude and prolong the duration of pain relief in patients with osteoarthritis of the knee.

Development Status and FDA Approval Process for Zilretta

DateArticle
May 26, 2016Flexion Therapeutics Receives Positive Guidance from FDA on NDA Submission for Zilretta for Osteoarthritis of the Knee
Feb 16, 2016Flexion Therapeutics Reports Primary Endpoint Met in Pivotal Phase 3 Trial of Zilretta in Knee Osteoarthritis
Dec  1, 2015Flexion Therapeutics Enrolls First Patient in Pharmacokinetic Study of Zilretta for Osteoarthritis of the Knee
Sep  8, 2015Flexion Therapeutics Reports Top-Line Data From Pivotal Phase 2b Clinical Trial for FX006
Feb 24, 2015Flexion Therapeutics Completes Enrollment in Pivotal Phase 2b Confirmatory Clinical Trial With Lead Compound FX006
Apr 19, 2013Data Presented at OARSI's 2013 World Congress on Osteoarthritis Show Flexion's FX006 Has Prolonged Therapeutic Concentration in Knee Joint

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide